Treatment Guided by Comprehensive Genomic Profiling and Expert MTB Decision-Making Improves Outcomes in Pretreated Patients with Metastatic Cancer By Ogkologos - October 14, 2025 222 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ROME study Source RELATED ARTICLESMORE FROM AUTHOR FX-909 Demonstrates Acceptable Safety and Preliminary Antitumour Activity, Establishing a Proof of Concept for PPARγ Inverse Agonism in Advanced Urothelial Cancer Pimicotinib Shows Robust Antitumour Activity and Clinically Meaningful Improvements in Patients with Tenosynovial Giant Cell Tumour FDA Grants Accelerated Approval to Zongertinib for Unresectable or Metastatic Non-Squamous NSCLC MOST POPULAR 6-Year-Old Uses Money From Lemonade Stand To Take Mom Out On... August 6, 2019 EMA Recommends Granting a Marketing Authorisation for Biosimilar Pegfilgrastim September 18, 2025 FDA Grants Traditional Approval to Selpercatinib for RET Fusion-positive Thyroid Cancer July 2, 2024 Exposure to Antibiotics, Specifically Fluoroquinolones, Before Treatment with Immune Checkpoint Inhibitor... March 6, 2023 Load more HOT NEWS Whole- and Partial-Breast Radiation Effective at Preventing Breast Cancer from Returning Pembrolizumab Improves Survival in Patients from Asia with Previously Treated Advanced... Rare Disease Day: Raising Awareness for Rare Cancers Ralph, Medical Dog, Retires From Colorado Children’s Hospital To Focus On...
